Categories: Uncategorized

WHO seeks more info for emergency use listing of Covaxin

The World Health Organisation (WHO) has said more information is required from Bharat Biotech, which is seeking emergency use listing (EUL) for its Covaxin vaccine for COVID-19.

The latest Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process’ guidance document dated May 18 on the WHO website said Bharat Biotech submitted EOI (Expression of Interest) on April 19 and that more information required . A pre-submission meeting is expected to be planned May-June 2021, the guidance document said.

According to the WHO, submissions to it for prequalification or listing under the emergency use procedure are confidential.

If a product submitted for assessment is found to meet the criteria for listing, WHO will publish the results widely. Duration of the emergency use listing process depends on the quality of the data submitted by the vaccine manufacturer and on those data meeting WHO criteria, according to the agency.

Meanwhile, Hyderabad-based Bharat Biotech International Limited (BBIL) has conveyed to the government that it has already submitted 90 per cent of documents to WHO for obtaining emergency use listing (EUL) for the Covaxin vaccine, sources said in New Delhi on Monday.

The remaining documents are expected to be submitted by June, the Hyderabad-based Bharat Biotech Ltd told the Central government during a discussion on obtaining the World Health Organisation’s authorisation for emergency use listing for Covaxin, sources said.

“BBIL is confident about obtaining WHO’s emergency use listing,” said a source. Noting that Covaxin has already received regulatory approval from 11 countries, sources said there was also interest from other 11 companies in seven nations for technology transfer and production of Covaxin.

The company is in the final stages of negotiations with the Food and Drug Administration of the US for conducting small-scale phase-III clinical trials of Covaxin in the United States, sources said.

Sources said the meeting with BBIL on the EUL was attended by the company’s managing director V Krishna Mohan and his colleagues besides senior officers of the Ministry of Health, Department of Biotechnology and Ministry of External Affairs.

Foreign Secretary Harsh Vardhan Shringla was among those who attended the meeting.

Medically Speaking Team

Share
Published by
Medically Speaking Team

Recent Posts

The Hidden Costs of Excessive Screen Time: How It Impacts Your Child’s Behavior and What You Can Do About It

Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…

4 hours ago

Transform Your Heart Health: Simple Everyday Diet and Lifestyle Changes for a Happier, Stronger Heart

Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…

4 hours ago

“Unraveling the Truth: Do Brain Tumours Only Affect Older Adults? Debunking Myths and Shedding Light on a Complex Condition”

This article explores the common misconception that brain tumours primarily affect older adults, revealing the…

4 hours ago

“Revolutionary Breakthrough: First-Ever Ovarian Cancer Vaccine Set to Transform Women’s Health and Combat a Silent Killer”

The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…

5 hours ago

“Battling the Monsoon Surge: Essential Strategies to Prevent Dengue and Chikungunya Infections in Delhi”

As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…

5 hours ago

NATURAL vs CHEMICAL SKINCARE: THE ESSENTIAL GUIDE TO CHOOSING WHAT’S BEST FOR YOUR SKIN

Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…

5 hours ago